Currently, there are 122.22M common shares owned by the public and among those 120.10M shares have been available to trade.
The company’s stock has a 5-day price change of -10.50% and -25.44% over the past three months. HUM shares are trading -38.96% year to date (YTD), with the 12-month market performance down to -42.56% lower. It has a 12-month low price of $298.61 and touched a high of $530.54 over the same period. HUM has an average intraday trading volume of 1.24 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -14.98%, -19.97%, and -23.11% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Humana Inc. (NYSE: HUM) shares accounts for 95.60% of the company’s 122.22M shares outstanding.
It has a market capitalization of $33.65B and a beta (3y monthly) value of 0.50. The stock’s trailing 12-month PE ratio is 19.92, while the earnings-per-share (ttm) stands at $14.03. The company has a PEG of 4.06 and the debt-to-equity ratio at 0.77. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.49% over the week and 3.33% over the month.
Earnings per share for the fiscal year are expected to decrease by -37.97%, and 23.26% over the next financial year. EPS should shrink at an annualized rate of 4.90% over the next five years, compared to 10.46% over the past 5-year period.
Looking at the support for the HUM, a number of firms have released research notes about the stock. Piper Sandler stated their Overweight rating for the stock in a research note on June 26, 2024, with the firm’s price target at $392. Morgan Stanley coverage for the Humana Inc. (HUM) stock in a research note released on June 24, 2024 offered a Equal-Weight rating with a price target of $374. Raymond James on their part issued Mkt Perform rating on March 22, 2024.
